Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × Sulindac × Clear all

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

OTHER 9 NIH 4 NETWORK 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Paclitaxel 218 Carboplatin 215 Gemcitabine 202 Docetaxel 187 Cisplatin 186 Bevacizumab 182 pembrolizumab 181 Pemetrexed 131 Capecitabine 124 Fluorouracil 106 Cyclophosphamide 102 Oxaliplatin 99 Nivolumab 89 Dexamethasone 79 Leucovorin 75 Rituximab 69 Irinotecan 69 Trastuzumab 68 Cetuximab 65 Injections 64 Prednisone 60 Ipilimumab 57 Doxorubicin 56 atezolizumab 54 Temozolomide 54 Erlotinib Hydrochloride 54 Bortezomib 54 Radiotherapy 51 Fulvestrant 45 Drug Therapy 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡